Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment Article

Blank, Stephanie V, Christos, Paul, Curtin, John P et al. (2010). Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment . GYNECOLOGIC ONCOLOGY, 119(3), 451-456. 10.1016/j.ygyno.2010.08.008

Open Access

cited authors

  • Blank, Stephanie V; Christos, Paul; Curtin, John P; Goldman, Noah; Runowicz, Carolyn D; Sparano, Joseph A; Liebes, Leonard; Chen, Helen X; Muggia, Franco M

sustainable development goals

publication date

  • December 1, 2010

published in

keywords

  • AMPLIFICATION
  • CARCINOMA
  • CELL
  • CISPLATIN
  • Carboplatin
  • EXPRESSION
  • Erlotinib
  • HYDROCHLORIDE
  • IMPROVED SURVIVAL
  • Life Sciences & Biomedicine
  • Obstetrics & Gynecology
  • Oncology
  • Ovarian cancer
  • Paclitaxel
  • Reassessment surgery
  • STAGE-III
  • Science & Technology
  • TRIAL
  • TYROSINE KINASE INHIBITOR

Digital Object Identifier (DOI)

publisher

  • ACADEMIC PRESS INC ELSEVIER SCIENCE

start page

  • 451

end page

  • 456

volume

  • 119

issue

  • 3